-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Y-mAbs Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2018 to Q3 2024.
- Y-mAbs Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $0.000.
- Y-mAbs Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$18K, a 94.1% increase from 2021.
- Y-mAbs Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$304K.
- Y-mAbs Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2020 was $0.000.
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Quarterly (USD)